© 2023 MJH Life Sciences™ and Nutritional Outlook. All rights reserved.
A clinical trial recently published in the Journal of Arthritis showed that the patented eggshell membrane called NEM from Stratum Nutrition helped reduce pain and stiffness in the joints of osteoarthritis patients.
A clinical trial recently published in the Journal of Arthritis showed that the patented eggshell membrane called NEM from Stratum Nutrition (Carthage, MO) helped reduce pain and stiffness in the joints of osteoarthritis (OA) patients. In the study, 160 subjects over the age of 40 with grade 2 and 3 knee OA were randomized to receive either 500 mg of eggshell membrane or placebo for 30 days. After 30 days on placebo, the placebo group crossed over while remaining blinded and took 500 mg of eggshell membrane for an additional 60 days. The original eggshell membrane group would continue supplementation for the remaining 60 days. OA symptoms were assessed at baseline, day 7, day 30, and day 90 using the Western Ontario and McMaster Universities (WOMAC) OA index.
Results showed that subjects taking the eggshell membrane experience significant reductions in WOMAC-stiffness scores at day 7, compared to placebo, and WOMAC-total, -pain, -stiffness, and -function at day 30, compared to placebo. The number of subjects who experience decreases in WOMAC-pain groups was more than 20% greater in the 90-day eggshell membrane group (48%) compared to the 60-day eggshell membrane group (30%).
“This is the largest study conducted to date involving NEM and we are pleased that it was supportive of its fast time to efficacy, even in subjects with moderate to severe arthritis. This, combined with its cartilage protecting effects recently demonstrated in healthy individuals, makes NEM the perfect adjunctive therapy for those with joint issues,” said Kevin J. Ruff PhD, MBA, senior director of Scientific & Regulatory Affairs for Stratum Nutrition, in a press release.
1. Eskiyurt N. et al. “Efficacy and safety of natural eggshell membrane (NEM) in patients with grade 2/3 knee osteoarthritis: a multi-center, randomized, double-blind, placebo-controlled, single-crossover clinical study.” Journal of Arthritis, vol. 8, no. 4 (2019): 285